San Francisco startup Composition Therapeutics is additionally engaged on an oral, once-everyday GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-phase review confirmed normal weight loss of about six% and it options to start A further mid-stage demo toward the top of this yr—that founder and CEO